Q3 2024 Schrodinger Inc Earnings Call Transcript
Key Points
- Schrodinger Inc (SDGR) announced a significant collaboration with Novartis, which includes a $150 million upfront payment and potential for up to $2.3 billion in milestone payments.
- The company reported a 10% increase in software revenue for Q3, driven by increased hosted revenue and customer transitions to hosted software licenses.
- Schrodinger Inc (SDGR) added $48 million to its cash balance from the sale of Morphic to Lilly, bolstering its financial position.
- The company is advancing its proprietary pipeline with three clinical stage programs, with initial data expected in 2025.
- Schrodinger Inc (SDGR) has raised the lower end of its software revenue growth guidance for the year, indicating confidence in future performance.
- Software revenue for Q3 was slightly below expectations, partly due to slower recognition of revenue from the Gates Foundation grant.
- Drug discovery revenue was significantly lower in Q3 compared to the previous year, leading to a reduction in full-year guidance for this segment.
- The company's overall gross margin decreased to 50% in Q3, down from 56% a year ago, impacted by lower drug discovery revenue and software gross margin.
- Operating expenses increased, driven by higher R&D costs, contributing to an operating loss of $68.4 million for the quarter.
- Schrodinger Inc (SDGR) reported a net loss of $38 million for Q3, although this was an improvement from the previous year's loss.
Thank you for standing by. Welcome to Schrodinger's conference call to review our third-quarter 2024 financial results. My name is Madison, and I will be your operator for today's call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
Now I would like to introduce your host for today's conference, Ms. Jaren Madden, Senior Vice President in Investor Relations and Corporate Affairs. Please go ahead..
Thank you and good morning, everyone. Welcome to today's call during which we will provide an update on the company and review our third-quarter 2024 financial results. In addition to our press release announcing our third-quarter results, we also issued a press release announcing our new research collaboration and expanded software licensing agreement with Novartis. Both press releases are available on our website at schrodinger.com.
Here with me on our call today are Ramy Farid, Chief Executive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
